Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy

BACKGROUND: Patients with neuroimmunological conditions such as multiple sclerosis (MS) often receive disease-modifying therapies (DMTs) or immunosuppressants which may reduce the response to vaccines. BNT162b2 (Pfizer-BioNTech) is the first COVID-19 vaccine authorized in Italy. Its clinical efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Giossi, Riccardo, Consonni, Alessandra, Torri Clerici, Valentina, Zito, Antonio, Rigoni, Eleonora, Antozzi, Carlo, Brambilla, Laura, Crisafulli, Sebastiano Giuseppe, Bellino, Antonella, Frangiamore, Rita, Bonanno, Silvia, Vanoli, Fiammetta, Ciusani, Emilio, Corsini, Elena, Andreetta, Francesca, Baggi, Fulvio, Tramacere, Irene, Mantegazza, Renato, Conte, Antonella, Bergamaschi, Roberto, Confalonieri, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614185/
https://www.ncbi.nlm.nih.gov/pubmed/35216790
http://dx.doi.org/10.1016/j.msard.2021.103415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614185/
https://www.ncbi.nlm.nih.gov/pubmed/35216790
http://dx.doi.org/10.1016/j.msard.2021.103415

Ejemplares similares